{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:02:41Z","timestamp":1790683361998,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AbbVie, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40744-026-00880-z","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:29:06Z","timestamp":1787916546000},"page":"1341-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Steroid Burden, Treatment Patterns, and Rheumatologists\u2019 Perceptions on Advanced Therapy in Giant Cell Arteritis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-9290","authenticated-orcid":false,"given":"Anisha B.","family":"Dua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Zueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2226-8567","authenticated-orcid":false,"given":"Nathaniel","family":"Zerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arathi","family":"Setty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"1","key":"880_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03565-0","volume":"27","author":"JR Curtis","year":"2025","unstructured":"Curtis JR, Conrad DM, Krueger WS, Gara AP, Winthrop KL. Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster. Arthritis Res Ther. 2025;27(1):108.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"880_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02450-w","volume":"23","author":"KJ Li","year":"2021","unstructured":"Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23(1):82.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"880_CR3","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/ard-2022-223480","volume":"81","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology\/EULAR Classification Criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647\u201353.","journal-title":"Ann Rheum Dis"},{"key":"880_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186350","author":"M Shiomi","year":"2025","unstructured":"Shiomi M, Watanabe R, Ishihara R, et al. Uncovering the new biology of giant cell arteritis to guide therapeutic strategies. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14186350.","journal-title":"J Clin Med"},{"issue":"1","key":"880_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.revmed.2024.10.011","volume":"46","author":"H de Boysson","year":"2025","unstructured":"de Boysson H, Devauchelle-Pensec V, Agard C, et al. French protocol for the diagnosis and management of giant cell arteritis. Rev Med Interne. 2025;46(1):12\u201331.","journal-title":"Rev Med Interne"},{"key":"880_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.06.009","author":"CB Mukhtyar","year":"2026","unstructured":"Mukhtyar CB, Nikiphorou E, Bartoletti A, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Ann Rheum Dis. 2026. https:\/\/doi.org\/10.1016\/j.ard.2026.06.009.","journal-title":"Ann Rheum Dis"},{"key":"880_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041034","author":"P Castan","year":"2022","unstructured":"Castan P, Dumont A, Deshayes S, et al. Impact of glucocorticoid cumulative doses in a real-life cohort of patients affected by giant cell arteritis. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11041034.","journal-title":"J Clin Med"},{"issue":"9","key":"880_CR8","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1093\/rheumatology\/keab921","volume":"61","author":"H de Boysson","year":"2022","unstructured":"de Boysson H, Barakat C, Dumont A, et al. Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events. Rheumatology (Oxford). 2022;61(9):3567\u201375.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"880_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","volume":"5","author":"S Gale","year":"2018","unstructured":"Gale S, Wilson JC, Chia J, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther. 2018;5(2):327\u201340.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"880_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40744-025-00778-2","volume":"12","author":"JR Curtis","year":"2025","unstructured":"Curtis JR, Kruzikas DT, Romero A, et al. Real-world analysis of patient characteristics, adverse events, and economic burden among patients with giant cell arteritis treated with glucocorticoids. Rheumatol Ther. 2025;12(5):835\u201354.","journal-title":"Rheumatol Ther"},{"issue":"20","key":"880_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med. 2025;392(20):2013\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"880_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"880_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf128","volume":"9","author":"LM Zhu","year":"2025","unstructured":"Zhu LM, Mendel A, Ross C, Makhzoum JP. The effectiveness and safety of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis. Rheumatol Adv Pract. 2025;9(4):rkaf128.","journal-title":"Rheumatol Adv Pract"},{"key":"880_CR14","unstructured":"Genentech Inc. Actemra (tocilizumab) prescribing information. 2025."},{"key":"880_CR15","unstructured":"Roche Pharma AG. Roactemra (tocilizumab) summary of product characteristics. 2025."},{"issue":"8","key":"880_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"880_CR17","unstructured":"Samson M, Bourredjem A, Outh R, et al. Methotrexate versus tocilizumab for treatment of giant cell arteritis (METOGiA trial): a multicenter, randomized, controlled trial [abstract]. Arthritis Rheumatol. 2025;77(suppl 9.)."},{"key":"880_CR18","unstructured":"AbbVie. RINVOQ(R) (upadacitinib) receives U.S. FDA approval for giant cell arteritis (GCA). 2025. https:\/\/news.abbvie.com\/2025-04-29-RINVOQ-R-upadacitinib-Receives-U-S-FDA-Approval-for-Giant-Cell-Arteritis-GCA. Accessed 1 May 2026."},{"key":"880_CR19","unstructured":"AbbVie Deutschland GmbH & Co. RINVOQ summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf. Accessed 1 May 2026."},{"key":"880_CR20","unstructured":"AbbVie Inc., North Chicago, IL., USA. RINVOQ (upadacitinib) prescribing information. 2025. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 1 May 2026."},{"key":"880_CR21","doi-asserted-by":"crossref","unstructured":"Schmidt W, Setty AR, Dejaco C, et al. Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the re-randomized, double-blind select-GCA phase 3 trial [abstract]. Arthritis Rheumatol. 2025;77.","DOI":"10.1093\/rheumatology\/keag121.017"},{"issue":"3","key":"880_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1\u201323.","journal-title":"Rheumatology (Oxford)"},{"key":"880_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.732934","volume":"8","author":"A Mahr","year":"2021","unstructured":"Mahr A, Hachulla E, de Boysson H, et al. Presentation and real-world management of giant cell arteritis (ARTEMIS study). Front Med (Lausanne). 2021;8:732934.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"880_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","volume":"38","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38(4):569\u201377.","journal-title":"Rheumatol Int"},{"issue":"2 Suppl 89","key":"880_CR25","first-page":"S-98","volume":"33","author":"A Chandran","year":"2015","unstructured":"Chandran A, Udayakumar PD, Kermani TA, et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-98-102.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"880_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-021-00290-3","volume":"8","author":"G Craig","year":"2021","unstructured":"Craig G, Knapp K, Salim B, Mohan SV, Michalska M. Treatment patterns, disease burden, and outcomes in patients with giant cell arteritis and polymyalgia rheumatica: a real-world, electronic health record-based study of patients in clinical practice. Rheumatol Ther. 2021;8(1):529\u201339.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"880_CR27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR Task Force. Ann Rheum Dis. 2016;75(6):952\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"880_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MD.0000000000000033","volume":"93","author":"MA Alba","year":"2014","unstructured":"Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194\u2013201.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"880_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00296-023-05527-8","volume":"44","author":"C Tsalapaki","year":"2024","unstructured":"Tsalapaki C, Lazarini A, Argyriou E, et al. Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis. Rheumatol Int. 2024;44(4):603\u201310.","journal-title":"Rheumatol Int"},{"issue":"2","key":"880_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"C Labarca","year":"2016","unstructured":"Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2016;55(2):347\u201356.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00880-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:29:16Z","timestamp":1790681356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00880-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00880-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B. Dua has received consulting fees from AbbVie, Amgen, AZ, GSK, Novartis, and Sanofi; has participated in clinical trials or received grant support from Amgen, Novartis, and Rheumatology Research Foundation; and was on the Board of Directors for Vasculitis Foundation and Rheumatology Research Foundation. A. Kadakia, P. Zueger, N. Zerad, and A. Setty are employees of AbbVie and may own stock or stock options. S. Marwaha is a former employee of Adelphi Real World and current employee of Research Partnership. W. Jones is an employee of Adelphi Real World. V. Devauchelle-Pensec has received grants from Fresenius and consultancy fees from AbbVie and Novartis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided informed consent for use of their anonymized and aggregated data for research and scientific publication. All data were collected, aggregated, and de-identified prior to receipt. Data collection was performed in line with national market research and privacy regulations according to the European Pharmaceutical Marketing Research Association guidelines, and ethical exemption was sought from the Pearl Institutional Review Board. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing services were provided by Samantha D. Francis Stuart, PhD, of Avalere Health, Ltd., and funded by AbbVie.","order":3,"name":"Ethics","label":"Medical Writing, Editorial, and Other Assistance","group":{"name":"EthicsHeading","label":"Declarations"}}]}}